Skip to content

Content

How true is the claim that 'weight loss injections cause blindness'?

SDGS IconSDGS IconSDGS IconSDGS IconSDGS Icon

Weight loss injections, widely used in the treatment of obesity and diabetes in recent years, are back on the agenda due to the risk of vision loss. The US Food and Drug Administration's (FDA) request on November 9, 2026, to add a warning regarding a serious eye disease to the product information of GLP-1 group drugs has raised public concern. 

Evaluating the issue in light of scientific data, Prof. Tayfun Uzbay, Head of the Department of Medical Pharmacology, stated that the vision loss risk associated with these drugs is very rare but can lead to permanent consequences, saying, “The generalization that weight loss injections cause blindness is not scientifically accurate. However, there is some noteworthy data indicating that some GLP-1 receptor agonists may increase the risk of ischemic optic neuropathy, which is very rare and can cause permanent vision loss. The FDA's new warning should therefore be taken into consideration.”
 

Prof. Tayfun Uzbay, Advisor to the President of Üsküdar University, Head of the Department of Internal Medical Sciences and Medical Pharmacology at the Faculty of Medicine, evaluated the discussions regarding weight loss injections potentially causing vision loss and the FDA's new drug safety warning.

Does the claim 'weight loss injections cause blindness' reflect the truth?

Prof. Tayfun Uzbay stated that there is a genuine pharmacovigilance warning behind the news of vision loss associated with weight loss injections, adding, “However, the phrase 'weight loss injections cause blindness' used in the media goes far beyond scientific data and is exaggerated to the extent that it can create unnecessary public concern.”

Uzbay reminded that the FDA requested new warnings regarding the risk of serious vision loss to be added to the product information of GLP-1 receptor agonists on November 9, 2026, and stated that the European Medicines Agency (EMA) made a similar assessment regarding semaglutide-containing drugs in June 2025.

Prof. Uzbay stated that the risk in question is associated with an eye disease called non-arteritic anterior ischemic optic neuropathy (NAION), and continued as follows:

“In this disease, sudden and painless vision loss typically occurs in one eye due to insufficient blood flow to the anterior part of the optic nerve. A part of the visual field may be lost, and some patients may develop permanent, severe vision loss. The development of NAION does not mean that every patient will become completely blind. However, even a rare risk is important for drug safety because its consequences can be irreversible.”

What was found in the 126 clinical studies reviewed by the FDA?

Prof. Uzbay stated that the FDA based its decision on comprehensive scientific evaluations, reporting that 126 randomized controlled clinical studies were reviewed together.

Prof. Uzbay stated that the data of 78,217 people using GLP-1 group drugs and 56,036 people in the comparison group were evaluated in these studies, and noted that 10 NAION cases were detected in drug users and 5 in the comparison group.

Prof. Uzbay pointed out that according to the results, 6.4 NAION cases per 100,000 people were observed in GLP-1 users, while 3.8 cases were seen in the comparison group, and stated that these numbers indicated an increase in risk, but the findings should be interpreted cautiously due to the very low total number of cases.

Risk can nearly double in diabetic patients!

Prof. Uzbay reminded that EMA reported the NAION risk could approximately double in type 2 diabetic patients using semaglutide, and noted that the absolute risk increase is quite low.

Prof. Uzbay stated that this increase corresponds to approximately one additional case per 10,000 person-years of treatment, emphasizing that this refers not to the total number of cases, but to the estimated additional risk associated with drug use.

Referring also to the meta-analysis published in the journal Ophthalmology in 2026, which included observational data from more than 1.6 million people, Prof. Uzbay reported that while an increase in risk was observed in diabetic patients, a statistically significant increase could not be shown in individuals using semaglutide solely for weight control.

However, stating that this does not mean the risk is completely eliminated, Uzbay made the following assessment:

“An adverse clinical event occurring after the use of a drug does not, by itself, prove the direct toxic effect of that drug. But a repeated increase in risk in reliable studies cannot be ignored either.”

Adding a warning to the leaflet does not mean the drug is banned!

Prof. Uzbay stated that the FDA's warning was not limited to semaglutide but also covered drugs such as liraglutide, dulaglutide, and tirzepatide, adding that this does not mean all drugs have been proven to carry the same level of risk.

Uzbay noted that the strongest epidemiological data currently relate to semaglutide, and uncertainties regarding the individual risks of other drugs persist, adding that the NAION warning has also been reflected in the official product information of semaglutide-containing drugs in Turkey.

Prof. Uzbay explained how drug safety warnings should be interpreted:

“Adding a warning to the leaflet does not mean the drug is banned or its license revoked. The purpose of pharmacovigilance is to reflect newly identified risks in the clinician's and patient's decision-making.”

The exact cause of optic nerve damage is not yet fully known!

Prof. Uzbay stated that the mechanism by which GLP-1 receptor agonists might increase the risk of NAION has not yet been fully elucidated, and that different possibilities are being evaluated in scientific research.

Prof. Uzbay stated that the drugs' ability to lower blood pressure, cause fluid loss in some individuals, or increase nocturnal hypotension could negatively affect the blood circulation of the optic nerve in susceptible patients, but emphasized that this mechanism has not been proven.

Prof. Uzbay stated that there are evaluations indicating that a rapid drop in blood sugar, especially in diabetic patients, could create temporary circulatory problems in previously damaged small vessels, and spoke as follows:

“Diabetes, hypertension, obesity, sleep apnea, and vascular diseases also pose a risk for NAION. Therefore, it is difficult to distinguish how much of the cases observed in individuals using these drugs are due to the drug and how much are due to underlying diseases.”

Not every vision loss is the same disease!

Uzbay also pointed out that eye problems associated with semaglutide should not be confused with each other, stating that diabetic retinopathy and NAION are different diseases.

Prof. Uzbay stated that diabetic retinopathy affects the retinal vessels, while NAION affects the optic nerve, and added that the mechanisms of onset for these two clinical pictures cannot be considered the same.

Prof. Uzbay stated that addressing different eye diseases under a single 'vision loss' heading in the media could lead to incorrect evaluations, and emphasized that patients should be informed in line with scientific data.

If sudden and painless vision loss occurs, a doctor should be consulted on the same day!

Prof. Uzbay also explained which symptoms individuals using GLP-1 group drugs should pay attention to, stating that sudden and painless vision loss, especially in one eye, should be taken seriously.

Uzbay stated that in cases of partial visual field loss or sudden visual disturbances, an emergency ophthalmological evaluation should be performed on the same day, and emphasized that the treatment decision should be made by specialist physicians.

Prof. Uzbay noted that routine eye examinations are not recommended for everyone starting treatment solely to assess NAION risk, and stated that individual risk assessment is important in people with diabetes, hypertension, obesity, sleep apnea, and vascular disease.
Uzbay stated that if a diagnosis of NAION is confirmed, the EMA recommends discontinuing semaglutide treatment, while the FDA has reported that discontinuation of GLP-1 group drugs should be considered, and the option of continuing treatment may be entertained in cases where the benefits clearly outweigh the risks.

'It is not right for patients to discontinue their medications out of fear!'

Prof. Uzbay stated that semaglutide and similar drugs have proven benefits in the treatment of obesity and type 2 diabetes, and reminded that significant benefits have also been shown on the risks of heart attack, stroke, and cardiovascular death in some patient groups with high cardiovascular risk.

Therefore, Uzbay emphasized that it is not scientifically correct for all patients to discontinue their treatments based on a very rare side effect, and stated that the benefit-risk balance of the drugs should be evaluated on an individual basis.

Prof. Uzbay pointed out the importance of endocrinology and ophthalmology specialists evaluating cases together when necessary.

Is there still a risk of vision loss years after stopping the medication?

Prof. Uzbay stated that another issue of public curiosity is whether vision loss might develop in the period after stopping the drugs, and said that current scientific studies focus mostly on cases occurring during drug use.

Uzbay stated that there is no scientific evidence showing that the drug causes blindness or vision loss years after being used for six months or a year and then discontinued, but noted that new research is needed to clarify long-term risks after treatment.

'These drugs are not cosmetic weight loss tools!'

Prof. Tayfun Uzbay stated that the increasing prevalence of weight loss injections in society creates new responsibilities in terms of drug safety, and said, “The generalization that weight loss injections cause blindness is not scientifically accurate. However, there is some noteworthy data indicating that some GLP-1 receptor agonists may increase the risk of ischemic optic neuropathy, which is very rare and can cause permanent vision loss. The FDA's new warning should therefore be taken into consideration. The issue we have not yet definitively established here is by what mechanism these drugs might cause this disease. On the other hand, we cannot ignore the serious benefits of these drugs in the treatment of obesity and diabetes. The correct approach is not to frighten patients, but to inform them in light of scientific data and to prevent the use of drugs without medical supervision.”

Prof. Uzbay stated that while on one hand, drugs are presented as almost completely risk-free weight loss products, on the other hand, unnecessary fear is created in society through very rare side effects, and said that both approaches are incorrect.

Uzbay said, “What is important in drug safety is not to deny or exaggerate the existence of a risk, but to correctly evaluate the magnitude of that risk, the level of evidence, and its relationship with the benefits provided by the treatment,” and added that the continuous monitoring of the safety of these drugs, which are rapidly gaining widespread use in society, after licensing is of great importance for the protection of public health. 
 

Üsküdar News Agency (ÜHA)

Share

Creation Date: November 20, 2026

Request a Call

Phone